| scholarly article | Q13442814 |
| P356 | DOI | 10.1111/J.1600-6143.2007.01923.X |
| P698 | PubMed publication ID | 17845564 |
| P50 | author | Peter Senior | Q43166732 |
| P2093 | author name string | Salam A | |
| Campbell PM | |||
| Kneteman NM | |||
| Shapiro AM | |||
| Ryan EA | |||
| Imes S | |||
| Halpin A | |||
| Bigam DL | |||
| Labranche K | |||
| P433 | issue | 10 | |
| P304 | page(s) | 2311-2317 | |
| P577 | publication date | 2007-10-01 | |
| P1433 | published in | American Journal of Transplantation | Q4744273 |
| P1476 | title | High risk of sensitization after failed islet transplantation | |
| P478 | volume | 7 |
| Q34170266 | A simplified approach to human islet quality assessment |
| Q36796037 | Alloantibody and autoantibody monitoring predicts islet transplantation outcome in human type 1 diabetes |
| Q90484868 | Anti-inflammatory Approach With Early Double Cytokine Blockade (IL-1β and TNF-α) Is Safe and Facilitates Engraftment in Islet Allotransplantation |
| Q37528715 | Autologous and Allogenous Antibodies in Lung and Islet Cell Transplantation. |
| Q58763032 | Biomarkers in Islet Cell Transplantation for Type 1 Diabetes |
| Q36069444 | CTLA4Ig prevents alloantibody formation following nonhuman primate islet transplantation using the CD40-specific antibody 3A8 |
| Q33869805 | Caspase inhibitor therapy synergizes with costimulation blockade to promote indefinite islet allograft survival |
| Q37671887 | Cell therapy for type 1 diabetes |
| Q39005220 | Clinical pancreatic islet transplantation. |
| Q42555409 | Counterpoint: clinical islet transplantation: not ready for prime time |
| Q37360411 | Current advances and travails in islet transplantation |
| Q87039180 | Current status of clinical islet transplantation |
| Q37333994 | De Novo Donor-Specific HLA Antibody Formation in Two Patients With Crigler-Najjar Syndrome Type I Following Human Hepatocyte Transplantation With Partial Hepatectomy Preconditioning |
| Q46700614 | Decision time for pancreatic islet-cell transplantation |
| Q37360397 | Differences in baseline lymphocyte counts and autoreactivity are associated with differences in outcome of islet cell transplantation in type 1 diabetic patients |
| Q36936238 | ECDI-fixed allogeneic splenocytes induce donor-specific tolerance for long-term survival of islet transplants via two distinct mechanisms |
| Q34284604 | Effect of Triple Costimulation Blockade on Islet Allograft Survival in Sensitized Mice |
| Q34374773 | Evaluating protocols for embryonic stem cell differentiation into insulin-secreting beta-cells using insulin II-GFP as a specific and noninvasive reporter |
| Q30430239 | Evolution of β-Cell Replacement Therapy in Diabetes Mellitus: Islet Cell Transplantation |
| Q36711245 | Five-year follow-up of patients with type 1 diabetes transplanted with allogeneic islets: the UIC experience |
| Q30405787 | HLA class I sensitization in islet transplant recipients: report from the Collaborative Islet Transplant Registry |
| Q36492605 | How regenerative medicine and tissue engineering may complement the available armamentarium in gastroenterology? |
| Q38128768 | Immune monitoring of islet and pancreas transplant recipients |
| Q84547719 | Immune responses against islet allografts during tapering of immunosuppression--a pilot study in 5 subjects |
| Q36756541 | Immunoglobulin-like transcript 3-Fc suppresses T-cell responses to allogeneic human islet transplants in hu-NOD/SCID mice |
| Q30418470 | Improvement in outcomes of clinical islet transplantation: 1999-2010. |
| Q87388246 | Induction of antigen-specific human T suppressor cells by membrane and soluble ILT3 |
| Q34591457 | Insulin-producing cells could not mimic the physiological regulation of insulin secretion performed by pancreatic beta cells |
| Q42920020 | Islet Transplantation Using Donors After Cardiac Death: Report of the Japan Islet Transplantation Registry |
| Q44135951 | Islet allograft rejection in sensitized mice is refractory to control by combination therapy of immune-modulating agents |
| Q37088225 | Islet transplantation in type 1 diabetes: ongoing challenges, refined procedures, and long-term outcome |
| Q34976218 | Islet transplantation in type 1 diabetic patients using calcineurin inhibitor-free immunosuppressive protocols based on T-cell adhesion or costimulation blockade |
| Q34026630 | Islet transplantation in type 1 diabetics using an immunosuppressive protocol based on the anti-LFA-1 antibody efalizumab |
| Q35855470 | Islet transplantation in type I diabetes mellitus |
| Q82116010 | Islet transplantation--the imperative need for continued clinical trials |
| Q57702344 | Islet transplantation: need for a time-out? |
| Q36930342 | Islet-after-failed-pancreas and pancreas-after-failed islet transplantation: Two complementary rescue strategies to control diabetes. |
| Q34340690 | Mesenchymal stem cells as feeder cells for pancreatic islet transplants |
| Q84456399 | Minimising the clinical impact of the alloimmune response through effective histocompatibility testing for organ transplantation |
| Q42594941 | Oleanolic Acid, a plant triterpenoid, significantly improves survival and function of islet allograft. |
| Q37670775 | Pancreas transplantation: solid organ and islet. |
| Q90429872 | Pancreatic Islet Transplantation in Humans: Recent Progress and Future Directions |
| Q42555736 | Point: steady progress and current challenges in clinical islet transplantation |
| Q34729434 | RNA interference for improving the outcome of islet transplantation. |
| Q38156830 | Recent progress in pancreatic islet transplantation |
| Q84521077 | Relative reductions in soluble CD30 levels post-transplant predict acute graft function in islet allograft recipients receiving three different immunosuppression protocols |
| Q26769878 | Report from IPITA-TTS Opinion Leaders Meeting on the Future of β-Cell Replacement |
| Q82591348 | Studies of circulating microparticle release in peripheral blood after pancreatic islet transplantation |
| Q37102844 | Subcutaneous transplantation of embryonic pancreas for correction of type 1 diabetes |
| Q55195472 | Therapeutic Potential of Ginsenosides as an Adjuvant Treatment for Diabetes. |
| Q35008270 | Toward the development of a global induced pluripotent stem cell library |
| Q46038349 | [Pancreas and islet transplantation]. |
| Q39642946 | mTOR Inhibition Suppresses Posttransplant Alloantibody Production Through Direct Inhibition of Alloprimed B Cells and Sparing of CD8+ Antibody-Suppressing T cells. |
Search more.